10936117

Source:http://linkedlifedata.com/resource/pubmed/id/10936117

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0004096, umls-concept:C0021461, umls-concept:C0030705, umls-concept:C0032861, umls-concept:C0036043, umls-concept:C0117996, umls-concept:C0205081, umls-concept:C0443252, umls-concept:C0585361, umls-concept:C1521801
pubmed:issue	2
pubmed:dateCreated	2000-9-5
pubmed:abstractText	To evaluate the efficacy and safety of fluticasone propionate administered as a once-daily or twice-daily regimen over a period of 1 year to patients with moderate asthma.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/10936117-11243993
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0231335
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists, http://linkedlifedata.com/resource/pubmed/chemical/Albuterol, http://linkedlifedata.com/resource/pubmed/chemical/Androstadienes, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Asthmatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Powders, http://linkedlifedata.com/resource/pubmed/chemical/fluticasone
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	0012-3692
pubmed:author	pubmed-author:AdelglassJJ, pubmed-author:CliffordD PDP, pubmed-author:DukeS PSP, pubmed-author:FarjoPP, pubmed-author:HardingS MSM, pubmed-author:WarkH JHJ, pubmed-author:ZuWallackRR
pubmed:issnType	Print
pubmed:volume	118
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	303-12
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:10936117-Administration, Inhalation, pubmed-meshheading:10936117-Adolescent, pubmed-meshheading:10936117-Adrenergic beta-Agonists, pubmed-meshheading:10936117-Adult, pubmed-meshheading:10936117-Aged, pubmed-meshheading:10936117-Albuterol, pubmed-meshheading:10936117-Androstadienes, pubmed-meshheading:10936117-Anti-Asthmatic Agents, pubmed-meshheading:10936117-Asthma, pubmed-meshheading:10936117-Child, pubmed-meshheading:10936117-Circadian Rhythm, pubmed-meshheading:10936117-Double-Blind Method, pubmed-meshheading:10936117-Drug Administration Schedule, pubmed-meshheading:10936117-Female, pubmed-meshheading:10936117-Follow-Up Studies, pubmed-meshheading:10936117-Forced Expiratory Volume, pubmed-meshheading:10936117-Humans, pubmed-meshheading:10936117-Male, pubmed-meshheading:10936117-Middle Aged, pubmed-meshheading:10936117-Nebulizers and Vaporizers, pubmed-meshheading:10936117-Powders, pubmed-meshheading:10936117-Safety, pubmed-meshheading:10936117-Severity of Illness Index
pubmed:year	2000
pubmed:articleTitle	Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.
pubmed:affiliation	Saint Francis Hospital & Medical Center, Hartford, CT 06105, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study